Search This Blog

Tuesday, July 9, 2024

'Stephanopoulos says ‘I don’t think’ Biden can serve 4 more years after ABC interview'

 ABC News anchor George Stephanopoulos admitted Tuesday that he does not believe President Biden can serve out a second term — days after conducting a closely watched interview with the commander-in-chief following his disastrous debate performance against Donald Trump last month.

Stephanopoulos, 63, was recorded by TMZ answering a question from a passer-by about Biden’s political future in midtown Manhattan.

“Do you think Biden should step down?” the anonymous interrogator asked the “Good Morning America” co-host and “This Week” moderator. “You’ve talked to him more than anybody else has lately.”

An estimated 8.5 million Americans watched Stephanopoulos’ 22-minute post-debate interview with Biden, which aired in full July 5 and was rebroadcast on “This Week” the following Sunday.Getty Images
Biden also claimed that his frequent errors were a “bad episode” rather than a sign of permanent deterioration, but declined to submit to a cognitive exam to prove that statement.ABC

“I don’t think he can serve four more years,” the soft-spoken Stephanopoulos responded after a pause.

“You don’t think he can serve four more years?” the questioner repeated before adding: “All right, that’s an answer.”

An estimated 8.5 million Americans watched Stephanopoulos’ 22-minute post-debate interview with Biden, which aired in full July 5 and was rebroadcast on “This Week” the following Sunday.

Biden also claimed that his frequent errors were a “bad episode” rather than a sign of permanent deterioration, but declined to submit to a cognitive exam to prove that statement.

“I don’t think he can serve four more years,” the soft-spoken Stephanopoulos responded after a pause.ABC

“Look, I have a cognitive test every single day,” Biden told Stephanopoulos, a former White House communications director in the Clinton administration who has worked for ABC in various capacities since 1997. “Every day, I’ve had tests. Everything I do. You know, not only am I campaigning, I’m running the world. And that’s not — it sounds like hyperbole, but we are the central nation of the world.”

https://nypost.com/2024/07/09/us-news/george-stephanopoulos-says-i-dont-think-biden-can-serve-4-more-years-after-abc-interview/

KUDLOW: There's nothing inflationary about Trump's "America First" platform

 There's nothing inflationary about Trump's "America First" platform and that's the subject of the riff. 

If Donald Trump's economic policies generated less than 2% inflation during his first term, why is it that people on Wall Street and elsewhere keep telling us those same policies in a second term will be inflationary? I don't get it. Where's the logic?

In his first term, Trump slashed the corporate tax rate, executed across the board regulatory red-tape relief, promoted fossil fuel production, fought unfair trading practices and kept our southern border relatively closed. The average inflation rate over his entire four-year term was 1.9% at an annual rate. The sum-total of consumer price increases was 7% for four years! 


Now, reading through Mr. Trump's newly released platform, under "Chapter 3: Build the Greatest Economy in History," his agenda rests on five pillars: slashing regulations, cutting taxes, securing fair trade deals, "drill, baby, drill," and, importantly, keep the U.S. dollar as the world's reserve currency (a.k.a. -- King Dollar!) So, tell me again where the inflation is going to come from? 

If Mr. Trump's trade policy is reciprocity, slapping tariffs on countries with unfair trading practices, that's not going to cause inflation. Consumers will boycott high prices, forcing businesses to cut back on their margins, or Chinese companies, for example, will have to cut their prices and profit margins. That's not inflationary. 

The only real cause of inflation is if the Federal Reserve starts printing boatloads of excess money, but if Mr. Trump wants the American dollar to be "America First" in world currency markets, that's not going to permit the Fed to go berserk in creating unwanted dollars. 

By the way, in Mr. Trump's platform documents, he talks several times about curbing unnecessary and wasteful spending. Again and again, the platform talks about defeating inflation and, as he turns the fossil spigots back on, oil prices could drop closer to $40 a barrel than to $85 to $100 a barrel. That is major league counter inflation and preserving Mr. Trump's corporate tax cuts, as well as restoring capital depreciation bonuses -- that will raise real worker wages, as it did in the first term, and enhance productivity as a result of the buildup of innovation and investment. 

That whole process is counter inflationary. Stopping Mr. Biden's border catastrophe will restore law and order and public safety and that is like a tax cut for families and small businesses, which is always counter inflationary. 

Meanwhile, open borders are not the pro-growth labor tool that some left-wing economists think it is, but it sure has increased federal, state, and local spending on food, housing, and healthcare, crowding out traditional entitlements, and raising prices in many of those areas. Especially housing! 

I remember the so-called smart money on Wall Street was opposed to Donald Trump back in 2016 and thought his corporate tax cuts would just boost deficits and inflation. They were wrong then, and they are wrong again now. 

https://www.foxbusiness.com/media/larry-kudlow-theres-nothing-inflationary-about-trumps-america-first-platform

Restaurant Stocks Slide As Wall Street Sours On Consumer

 The middle class is struggling under the burden of elevated inflation and high interest rates, and Wall Street analysts are increasingly worried about a slowdown in consumer spending. Warning signs are only getting louder by the week.

We've detailed for months about the onset of a consumer slowdown:

Earlier today, shares of consumer products company Helen of Troy crashed after missing earnings expectations and slashed its full-year outlook on "softer consumer demand" and "shifts in consumer spending." 

Fears of a slowdown also sparked selling in S&P 1500 Restaurants Index (S15REST) in late afternoon trading, down nearly 2%, marking its lowest intraday level since November 1. This decline negatively diverges S&P 500, which is being driven higher and higher by Mag7 and AI stocks. 

This won't end well... 

Here is a detailed list from Bloomberg featuring industry insights from Wall Street analysts on how fears of a consumer slowdown are pressuring restaurant stocks lower:

Piper Sandler, Brian Mullan

  • June traffic trends for casual dining, family dining, fine dining, and quick service establishments failed to show "any real evidence of noteworthy improvement" from "uninspiring" May, writes Mullan, who in his research note references data from Placer.ai, Blackbox, and Technomic

  • Says traffic in the quick service — or fast food — space has seemingly "gotten a bit worse" in 2Q vs 1Q

Gordon Haskett, Jeffrey Farmer

  • Cut price target on fast-food giant McDonald's, writing that the initial customer response to the company's $5 meal deal has been "underwhelming"

Truist Securities, Jake Bartlett

  • Cut price targets for McDonald's and Burger King owner Restaurant Brands International, saying their promotions don't appear to be boosting sales

KeyBanc, Eric Gonzalez

  • Writes that investor sentiment is "poor" on global fast food names and says "2Q will likely be one to forget"

  • "We believe several brands within our coverage universe are at risk of missing consensus same-store sales forecasts for the 2Q," including McDonald's, Burger King, Wendy's, Starbucks, KFC U.S. (owned by Yum! Brands), Papa Johns, and Dine Brands' Applebee's

Baird, David Tarantino

  • "Our most recent weekly private chain survey revealed overall comps below the averages for June/2Q," he writes

  • The data may include some "July 4 calendar noise," but Tarantino says the trend is "worth monitoring closely in upcoming weeks given our continued concerns about the economy and the possibility that some newer headwinds on consumer confidence have emerged amid an increasingly uncertain political backdrop"

As tighter monetary policy comes into play, with prior interest rate hikes filtering into the real economy in lags, consumer wallets will continue to tighten throughout the year. This will force consumers to make tough choices and reduce discretionary spending, such as dining out. 

https://www.zerohedge.com/markets/restaurant-slide-wall-street-sours-consumer

'FDA Updates Guidance to Further Empower Companies to Address the Spread of Misinformation'

 Today, the U.S. Food and Drug Administration is advancing its mission of ensuring the public has access to accurate, up-to-date science-based information to inform decisions about FDA-regulated medical products to maintain and improve their health. The agency is providing updated recommendations to empower industry seeking to voluntarily address misinformation about or related to their approved/cleared medical products. 

“Regulated industry plays a critical role in ensuring consumers have accurate information about medical products. We’ve updated our draft guidance to help further ensure industry has clarity and additional flexibility to promptly and proactively issue responsive communications to address misinformation they are seeing,” said FDA Commissioner Robert M. Califf, M.D. “The growing spread of rumors about science and medicine continues to put patients and consumers at risk. We remain steadfast in our commitment to address this public health concern and continue to support and encourage all parties in the public health ecosystem to take an active role.”

In today’s health care system, health care providers and consumers often turn to the internet to obtain health and medical-related information. However, not all information found online about medical products is reliable. There are many false statements and conclusions shared online and the structure and popularity of social media platforms have meant that false, inaccurate and/or misleading information about medical products can spread rapidly to a broad audience. Basing medical decisions on inaccurate information can have adverse consequences as it can lead patients and health care providers to choose treatments that are not safe and effective, or to forgo treatments that are. The FDA believes it is critically important to promptly address misinformation about medical products. The revised draft guidance issued today supports the efforts of medical product companies that share this interest in helping the public get factual, accurate and scientifically sound information about medical products. 

Specifically, the revised draft guidance, Addressing Misinformation About Medical Devices and Prescription Drugs Questions and Answers, sets out a policy that supports companies that issue certain kinds of internet-based communications (“tailored responsive communications”) to address internet-based misinformation about or related to their approved/cleared medical products when that misinformation is created or disseminated by an independent third party. For example, a company might choose to use this type of communication when a celebrity, healthcare provider or influencer, not acting on behalf of the company, posts false, inaccurate and/or misleading representations of fact about the company’s approved/cleared medical product on social media. Additionally, this revised draft guidance provides companies with many examples that illustrate the types of misinformation found online that a company might choose to address with a tailored responsive communication, along with some considerations relevant to the current digital information environment.

The revised draft guidance also describes existing avenues (“general medical product communications”) that companies might also choose to use to address misinformation about their medical products wherever that misinformation may appear. This draft guidance revises and replaces the draft guidance for industry, Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices, issued in June 2014. The revised draft guidance is open for public comment for 60 days.

In addition to providing these updated draft recommendations, the FDA has taken and will continue to take steps to communicate accurate, up-to-date, science-based information to the public. Some examples of such efforts include:  

  • Providing timely, digestible, factual information to news media and other organizations;
  • Creating resources on the FDA’s website and social media to address common questions about the products the agency regulates;
  • Participating in speaking engagements to draw attention to the dangers of misinformation and to provide factual information about FDA-regulated medical products and public health issues;
  • Providing interested parties with toolkits of resources; and
  • Posting memos and other regulatory documents that outline the agency’s decision-making, consistent with applicable law(s).

The FDA will continue to proactively offer resources about medical products to provide factual and scientifically sound information to the public. The agency remains committed to helping address misinformation and continues to support other interested parties that choose to engage on this critical issue.

Related Information

'What Should Be Done About Long-Term Care?'

 The problem of how to pay for long-term care continues to bedevil policy experts, with some arguing for a combination public-private insurance market and others arguing that a social insurance program is the best solution.

Marc Glickman, CEO of BuddyIns, a long-term care planning company, noted that a new type of hybrid long-term care/life insurance is picking up steam. "We are seeing a lot of growth in this 'combination' market, which combines life insurance with long-term care features," Glickman said Monday during a webinar hosted by the American Enterprise Institute (AEI). "And because of the competition in that space, the long-term care benefits for the premium dollar have actually rivaled -- and maybe even exceeded -- the amount of insurance coverage you can get from a traditional product."

Under such a "combination" product, a customer buys a set amount of life insurance, but if they need long-term care, the insurance company will "accelerate" the payout so it can be used to pay for that care, he explained. One advantage of these policies is that unlike traditional long-term care insurance policies -- which provide unlimited benefits and often see sharp rate increases because the cost of long-term care keeps going up -- the hybrid policies won't have big rate increases because they only pay out a set amount of money.

"For traditional policies, I think we've seen the worst of the rate increases," Glickman said. "You're still going to see them, but they're going to be milder and milder as they get more on track to be sustainable. What you're going to see on the hybrid market is a 'pre-built' policy that has guaranteed premiums built into it, where there can't be a rate increase, and that's, of course, very comforting to people that want a fixed outlay."

An Ongoing Need

The growth in long-term care offerings comes at a time when the need for long-term care insurance continues to grow. In 2021, the U.S. spent $467 billion on long-term care, said Mark Warshawsky, PhD, senior fellow at AEI, who cited numbers from CMS. Of that amount, $207 billion was financed by Medicaid, $93 billion was financed by Medicare, and $134 billion was paid from private funds, including $64 billion in costs paid out of pocket (Another $28 billion was listed as "other").

The risk of needing long-term care is greater throughout life for women than men, and at age 65 it stands at 64% for women and 49% for men, he continued. Black and Hispanic populations have about double the risk of other groups, Warshawsky said.

Medicaid, not Medicare, pays for 32% of long-term care -- of that, nearly two-thirds, or 60%, is spent on home care while the other 40% is used for nursing home care. Only about 11% of the population currently has a private long-term care policy, in part because medical underwriting requirements restrict eligibility, he said.

Attempts at Expansion Unsuccessful

Previous efforts to expand government coverage of long-term care have met with failure, Warshawsky noted. One early attempt in 1988 resulted in the passage of a bill in Congress, but that was repealed a year later when people realized it was going to be paid for by the elderly in the form of higher Medicare premiums.

More recently, a long-term care provision was included in the Affordable Care Act (ACA); it was a voluntary program that proponents hoped employers would offer to their employees. "The reason why it was included in ACA is it was thought to produce a lot of upfront revenue -- almost $70 billion -- for the ACA to pay for the expansion of health insurance," Warshawsky said. "As it turned out, a quick analysis showed that ... the program was not viable, there would be a lot of adverse selection. In other words, the people most at risk [of needing long-term care] would buy the insurance and others would stay away from it." The program was halted in 2011 and dropped from the law in 2013.

States have also looked at the issue, with Washington state currently implementing a long-term care insurance program known as WA Cares. It's a "modest" insurance policy paid for by mandatory payroll tax contributions, Warshawsky explained, adding that the program seemed to be "very unpopular" and there is currently a proposition on the state ballot to make the program voluntary.

What Happens Next?

With general agreement that the need for long-term care is only going to increase as the U.S. population ages, what should be done? Warshawsky said he recommends "self-reliance for those who can afford [to buy insurance] and appropriate assistance for those who cannot."

"I'm not proposing anything radical," he said. "We need to refocus Medicaid and get it back to what it was intended to be -- to help the poor and the middle class," rather than the current system which allows some wealthier people to retain their assets while still staying eligible for Medicaid.

But Wendell Primus, PhD, a visiting fellow at the Brookings Institution's Center on Health Policy, disagreed. "I think we need a social insurance answer, much like Social Security; this simply will not work in the private sector," he said.

And although this issue won't be addressed in the next election, "I do think that over the long run, in the next 10 to 15 years, we could see a solution here, mainly because this is expensive, and we don't have a solution right now," Primus said. "The numbers are going to put extreme burdens on [the Medicaid programs in] Florida, Arizona, and California, so I think there's going to be a need to tackle this issue just because of the cost and the fact that people haven't bought long-term care insurance, and I don't see any great reversal of that in the short run."

Any program that's developed will need to be mandatory "because almost by definition, there has to be a lot of [income] redistribution here," said Primus, who used to work on health policy issues for former House speaker Nancy Pelosi (D-Calif.). "I don't necessarily want to say redistribution is good, but because of the extreme cost, I don't think a low-income person can afford ... some of the cost of long-term care, and you're going to have to tax the higher-income individuals to make sure that you have adequate long-term provisions."

The benefit would include a defined set of services such as home care, adult day care, personal care services, homemaker services, care coordination, and transportation, Primus said. And it would need to be funded by a new trust fund similar to the current Hospital Insurance Trust Fund, with dedicated taxes.

On whom would the taxes be levied? "We think a federal income surcharge in the 5% to 7% range, starting at age 50 to 55," he said, noting that he was working on a proposal with his colleagues. "I don't think we should start that tax until age 50 or 55 because young families are having to buy a home, they're having to take care of [their children's] college education, and also, people don't start thinking about their long-term care needs until later in life. So I think politically, this would go down easier."

https://www.medpagetoday.com/publichealthpolicy/healthpolicy/110819

Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection

MICHAEL J. PELUSO HTTPS://ORCID.ORG/0000-0003-0585-6230DYLAN RYDER HTTPS://ORCID.ORG/0009-0008-4873-2493ROBERT R. FLAVELL HTTPS://ORCID.ORG/0000-0002-8694-1199YINGBING WANGJELENA LEVI HTTPS://ORCID.ORG/0000-0002-0846-0795BRIAN H. LAFRANCHI HTTPS://ORCID.ORG/0009-0007-2019-3494TYLER-MARIE DEVEAU HTTPS://ORCID.ORG/0000-0002-9834-8616AMANDA M. BUCK HTTPS://ORCID.ORG/0000-0001-7193-0617SADIE E. MUNTER, AND TIMOTHY J. HENRICH

DOI: 10.1126/scitranslmed.adk3295


Editor’s summary

The term “Long Covid” covers a diverse array of symptoms that an individual might experience weeks to years after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many drivers of Long Covid have been proposed, with supporting data for each. Here, Peluso et al. provide compelling evidence for two potential contributors: persistent SARS-CoV-2 and aberrant T cell activation. The authors used whole-body positron emission tomography imaging with a tracer that selectively tags activated T cells to show that those with Long Covid had certain tissues that were enriched for activated T cells in comparison with those without Long Covid. Moreover, because the gut was one of the sites of activated T cell enrichment, the authors analyzed gut biopsies from a subset of individuals with Long Covid. In these samples, the authors were able to identify the presence of SARS-CoV-2 RNA; this feature was consistent across all five samples analyzed. These data suggest that viral persistence and sustained immune activation are linked to Long Covid. —Courtney Malo

Abstract

The mechanisms of postacute medical conditions and unexplained symptoms after SARS-CoV-2 infection [Long Covid (LC)] are incompletely understood. There is growing evidence that viral persistence, immune dysregulation, and T cell dysfunction may play major roles. We performed whole-body positron emission tomography imaging in a well-characterized cohort of 24 participants at time points ranging from 27 to 910 days after acute SARS-CoV-2 infection using the radiopharmaceutical agent [18F]F-AraG, a selective tracer that allows for anatomical quantitation of activated T lymphocytes. Tracer uptake in the postacute COVID-19 group, which included those with and without continuing symptoms, was higher compared with prepandemic controls in many regions, including the brain stem, spinal cord, bone marrow, nasopharyngeal and hilar lymphoid tissue, cardiopulmonary tissues, and gut wall. T cell activation in the spinal cord and gut wall was associated with the presence of LC symptoms. In addition, tracer uptake in lung tissue was higher in those with persistent pulmonary symptoms specifically. Increased T cell activation in these tissues was also observed in many individuals without LC. Given the high [18F]F-AraG uptake detected in the gut, we obtained colorectal tissue for in situ hybridization of SARS-CoV-2 RNA and immunohistochemical studies in a subset of five participants with LC symptoms. We identified intracellular SARS-CoV-2 single-stranded spike protein–encoding RNA in rectosigmoid lamina propria tissue in all five participants and double-stranded spike protein–encoding RNA in three participants up to 676 days after initial COVID-19, suggesting that tissue viral persistence could be associated with long-term immunologic perturbations.